I Mab : Reports Third Quarter 2024 Results - MarketScreener

I Mab : Reports Third Quarter 2024 Results - MarketScreener

1 week from now

2 days ago  · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million, …

marketscreener.com

I-Mab Reports Third Quarter 2024 Results - Morningstar

1 week from now

2 days ago  · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

morningstar.com

I-Mab Reports Third Quarter 2024 Results - PR Newswire

1 week from now

2 days ago  · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024, the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

prnewswire.com

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024  · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

nasdaq.com

Invivyd Reports Third Quarter 2024 Financial Results And ... - Nasdaq

1 week from now

2 days ago  · Third Quarter 2024 Financial Results Revenue: Reported $9.3 million of net product revenue of PEMGARDA in Q3 2024 as compared to $2.3 million in Q2 2024. Cash Position: …

nasdaq.com

Beam Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

Nov 5, 2024  · Ended Third Quarter 2024 with $925.8 Million in Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027. Company to Host Conference …

yahoo.com

Invivyd Reports Third Quarter 2024 Financial Results And Recent ...

1 week from now

2 days ago  · Third Quarter 2024 Financial Results Revenue: Reported $9.3 million of net product revenue of PEMGARDA in Q3 2024 as compared to $2.3 million in Q2 2024. Cash Position: …

businessinsider.com

Apogee Therapeutics Provides Pipeline Progress And Reports Third ...

1 week from now

4 days ago  · Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2024 were $45.7 million, compared to $17.1 million for the third quarter of 2023. R&D …

businessinsider.com

ITeos Reports Third Quarter 2024 Financial Results And

1 week from now

4 days ago  · Third Quarter 2024 Financial Results Cash and Investment Position: The Company’s cash, cash equivalents, and investments position was $648.9 million as of September 30, …

globenewswire.com

Starco Brands Reports Third Quarter 2024 Financial Results

1 week from now

2 days ago  · Marketing, General and Administrative expenses were $4.2 million, or 27% of reported net revenue in the third quarter of 2024, compared to $5.0 million, or 28% of reported …

marketscreener.com